Gong et al. (2019) found that CRC patients in stages I-II presented with lower levels of tumor DUXAP8 than those in stage III-IV, and patients with larger tumor sizes expressed higher levels of DUXAP8. Another study demonstrated increased DUXAP8 expression in CRC tissues compared with paracarcinoma tissues, and showed that high DUXAP8 expression was indicative of shorter overall survival time (He et al., 2020). Here, DUXAP8 is linked to neoplasm.